弥漫大B细胞淋巴瘤研究最新进展

Progress of diffuse large B-cell lymphoma

弥漫大B细胞淋巴瘤（DLBCL）是成年人发生率最高的淋巴瘤亚型，是一组高度异质性的肿瘤，不同亚型有不同的生物学特征、临床表现及治疗反应，患者预后差别很大，尽管目前的标准治疗R-CHOP方案为基础的免疫化疗使DLBCL治愈率提高，但仍有约40％的患者治疗早期即出现耐药或达到缓解后复发，预后差。本文结合第59届美国血液学会（ASH）年会有关报道，对DLBCL的新分子分型、新靶点药物研发、复发难治患者治疗等的研究进展进行总结。

Diffuse large B-cell lymphoma （DLBCL） is the most common subtype of lymphoma in adults, which is a highly heterogeneous of lymphoma with different biological characteristics, clinical manifestations, response to treatment and different prognosis for different patients. Although the curative rate of DLBCL patients has been improved because of the immunotherapy based on the R-CHOP treatment, 40% of patients will be resistant to the treatment or relapse after the remission at the early stage with poor prognosis. This article summarizes the recent progress of DLBCL including new molecular typing, new target drug development and treatment of relapsed /refractory patients according to the 59th American Society of Hematology Annual Meeting.